Nerve Block for Total Knee Replacement

(CACB Trial)

This trial examines the effectiveness of a continuous adductor canal block, a pain-reduction method, for individuals undergoing knee replacement surgery. The researchers aim to determine if this method can reduce opioid use and enhance recovery. Participants will receive either a continuous nerve block or a placebo to compare outcomes. The trial is designed for those having a single knee replacement who can tolerate a small tube placed near their nerve for pain relief. The study seeks to identify better pain management options that could lead to quicker recovery and reduced reliance on strong pain medications. As an unphased trial, it offers a unique opportunity to advance pain management strategies for knee replacement patients.

The trial information does not specify if you need to stop taking your current medications. However, if you are using opioids regularly, you may not be eligible to participate.

Research shows that the continuous adductor canal block (CACB) is generally safe for people undergoing total knee replacement surgery. Studies have found that this method effectively reduces pain and decreases the need for opioids, which are strong painkillers with potential side effects. CACB appears to lower pain levels and aid in faster recovery after surgery.

Researchers are excited about the continuous adductor canal block (CACB) for total knee replacement because it offers a potentially more targeted way to manage post-surgery pain. Unlike traditional pain management methods like oral painkillers or epidurals, CACB specifically blocks nerve signals in a key area of the leg, which may reduce pain without affecting muscle strength or mobility. This localized approach could help patients recover faster and get back on their feet sooner, which is a significant improvement over current standard treatments.

Research has shown that a continuous adductor canal block (CACB), which participants in this trial may receive, provides better pain relief for individuals undergoing total knee replacement surgery. Studies have found that CACB offers longer-lasting pain control compared to single-injection methods, which typically stop working within 24 hours. One study found that CACB improves both pain and movement recovery after surgery. Another study suggested that CACB not only reduces the need for additional pain medication but also enhances the overall recovery experience. Overall, CACB appears to be a promising option for managing pain after knee replacement surgery.¹³⁴⁶⁷